Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01422161 · ClinicalTrials.gov registry record · Phase 3
Study of Botulinum Toxin and Recovery of Hand Function After Stroke
A Phase 3 study, sponsored by NYU Langone Health.
- Completed
- Registry status
- Phase 3
- Development phase
- 16
- Enrollment target
NCT01422161 is a Phase 3 study that has completed, run by NYU Langone Health. The registered enrollment target is 16 participants.
The verdict
NCT01422161, a Phase 3 study, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 16 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether injections of botulinum toxin (commonly known as BOTOX®) into the affected hand of Stroke patients, while targeting the muscles controlling the hand, will lead to improved use of the hand when compared to injections of placebo (a substance that looks similar to the study drug but contains no active study medication).
Interventions
- DRUG Placebo
- DRUG Botulinum Toxin commonly known as BOTOX®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2010-04 |
| Est. Completion | 2015-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01422161
The ClinicalTrials.gov registry entry for NCT01422161 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01422161 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01422161 about?
NCT01422161 is a clinical study titled "Study of Botulinum Toxin and Recovery of Hand Function After Stroke". The purpose of this study is to determine whether injections of botulinum toxin (commonly known as BOTOX®) into the affected hand of Stroke patients, while targeting the muscles controlling the hand, will lead to improved use of the hand when compared to injections of placebo (a substance that looks...
What is the current status of trial NCT01422161?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 16 participants. The study started on 2010-04. Estimated completion is 2015-10.
What interventions are being tested in trial NCT01422161?
The interventions under investigation include: Placebo (DRUG), Botulinum Toxin commonly known as BOTOX® (DRUG).
Who is sponsoring clinical trial NCT01422161?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.